



Feidhmeannacht na Seirbhíse Sláinte, Seirbhís Aisíocaíochta Cúraim Phríomhúil
Bealach amach 5, M50, An Bóthar Thuaidh, Fionnghlas
Baile Átha Cliath 11, D11 XKF3
Fón: (01) 864 7100 Facs: (01) 834 3589

Health Service Executive, Primary Care Reimbursement Service
Exit 5, M50, North Road, Finglas,
Dublin 11, D11 XKF3
Tel: (01) 864 7100 Fax: (01) 834 3589

Richard Bruton, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

12th November 2024

PQ: 44292/24

To ask the Minister for Health how his Department and the HSE plans to widen access to continuous glucose monitoring technology for people with Type 1 diabetes to improve their diabetes management and quality of life; and if he will make a statement on the matter. -Richard Bruton

Dear Deputy Bruton,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 44292/24), which you submitted to the Minister for Health for response.

Reimbursement of continuous glucose monitoring (CGM) sensors is supported for patients with Type 1 Diabetes Mellitus, in line with Circular 033/23 (attached).

Clinicians can apply through the secure portal for reimbursement support of CGM sensors to be considered under a person's community drug scheme eligibility.

Reimbursement of CGM at this point in time is for patients with Type I Diabetes Mellitus who have required insulin from the outset. Reimbursement does not extend to other cohorts who were not considered as part of the HIQA Health Technology Assessment (HTA). The published document can be found at <https://www.hiqa.ie/reports-and-publications/health-technology-assessment/rapid-healthtechnology-assessment-continuous>.

There has been an increase in utilisation and total expenditure on CGM sensors, under the Community Drug Schemes over the last three years. The number of individuals in receipt of CGM sensors under the Community Drug Schemes on a monthly basis between January 2021 and December 2023, increased from approximately 6,000 to 16,900, while total monthly expenditure increased from approximately €1.57 million to €5.35 million. Total expenditure on CGM sensors under the Community Drug Schemes in 2023 was approximately €55.7 million.

It is estimated that the cost of extending reimbursement eligibility for CGM sensors to all people in receipt of insulin under the Community Drug Schemes for one year would be in the region of €120 million.

The HSE Medicines Management Programme (MMP) have undertaken an evaluation to identify preferred CGM sensor(s) with associated system(s). This evaluation was published on 19/07/2024. This review included consideration of submissions from relevant stakeholders, including the suppliers of the CGM sensors, healthcare professional organisations and patient organisations.

<https://www.hse.ie/eng/about/who/cspd/medicines-management/glucose-monitoring/preferred-cgm-sensors/> “

Yours sincerely,



Suzanne Doyle
Primary Care Reimbursement Service

The Health Service Executive operates the General Medical Services Scheme, which includes Medical Cards and GP Visit Cards, under the Health Act 1970, as amended. It has established a dedicated contact service for members of the Oireachtas specifically for queries relating to the status of Medical Cards and GP Visit Cards applications, which the Deputy / Senator may wish to use for an earlier response. Tel: 01-8647180 / email: Oireachtas.pcrs@hse.ie